Navigation Links
Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that scientists from the company will present results of two preclinical studies with sapacitabine and seliciclib, the company's most advanced drug candidates in clinical development. The results will be reported in two poster presentations during the upcoming Annual Meeting of the American Association for Cancer Research (AACR) taking place at the Los Angeles Convention Center between April 14-18, 2007. Sapacitabine is an orally-available, novel nucleoside analog in Phase I clinical trials in patients with solid and hematological cancers. Seliciclib is the most advanced orally-available, cyclin dependent kinase (CDK) inhibitor in Phase II clinical development in patients with non-small cell lung cancer. Sapacitabine and seliciclib are the lead drug candidates in Cyclacel's pipeline of small molecule cell cycle inhibitors. -0-
The schedule of Cyclacel's presentations is as follows:


       Date          Time (PDT)          Title            Poster

                                                       Number/Session


Monday, April 16    1 PM - 5 PM   Identification of   # 3183

                                   biomarkers to aid  Poster Session

                                   clinical            24, South Hall

                                   development of

                                   sapacitabine

                                   (CYC682), a novel

                                   nucleoside analog


Tuesday, April 17   8 AM - 12 PM  Synergistic         # 4003

                                   combinations       Poster Session

                                   between the oral    31,

                                   CDK inhibitor,     South Hall

                                   seliciclib, and

                                   EGFR inhibitors in

                                   NSCLC


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:12/22/2014)... HOUSTON , Dec. 22, 2014 Cyberonics, Inc. ... devices for the treatment and management of epilepsy, today announced ... Morgan Healthcare Conference on Wednesday, January 14, 2015, in ... , Cyberonics, President and Chief Executive Officer, will speak at ... presentation can be accessed by clicking on the Investor Relations ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals Incorporated ... study of lonafarnib in patients with chronic hepatitis ... at the National Institutes of Health (NIH) Clinical ...  The double-blinded, randomized, placebo-controlled, dose ascending study evaluated ... and 200 mg twice daily for 28 days.  ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... 10 Inclinix, Inc., an,enrollment contract research organization ... today that it has received a patent,for its ... system that guides,interview questions during patient qualification for ... Inclinix advertises to recruit patients into clinical trials.,Respondents ...
... LC STAR nebulizer and,PRONEB Ultra II compressor ... (Nasdaq: ISPH ) second Phase 3 ... treatment. PARI reusable nebulizers are,considered the gold ... in,commercial sales including AstraZeneca,s Pulmicort Respules, Sepracor,s,Xopenex ...
Cached Medicine Technology:Inclinix Announces New Patent for Expert System Platform 2PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial 2
(Date:12/26/2014)... Yisrayl Hawkins, Pastor at The House of Yahweh in Abilene, ... Ferguson, Missouri unrest. Yisrayl starts his letter by showing the ... has only increased. , He continues in his letter ... is a very specific reason for mankind and covers those ... of rules, or Laws that if followed would ensure that ...
(Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... This is a professional and in-depth ... industry with a focus on the Chinese market. The ... the Sterilizers manufacturers and is a valuable source of ... the industry. This report provides a basic overview of ... In this part, the report presents the company profile, ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. TS-1 is an anti-cancer drug which ... administered orally and is also used for treating gastric ... gimestat and otastat potassium. The drug was first approved ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... taking a traditional Indian remedy for piles known as Endopile ... test of the drug, following a complaint, had revealed harmful ... been recalled from the Singapore market. The HSA said the ... ,The complaint came from a hospital that had treated a ...
... acids is claimed to prevent more sudden deaths ... even implanted defibrillators according to US scientists.// ... compared such preventive strategies by food supplementation and ... 100,000 people that resembled the population of Olmsted ...
... in the US do not wash their hands properly.// ... had conducted the survey of 8,000 people in eight countries. ... around U.S., U.K., Italy, Germany, United Arab Emirates, India, Malaysia, ... disinfectants, mouthwash, and cleaning products. In their survey they had ...
... and made available on the World Wide Web - a ... in the body. // ,The researchers had earlier identified ... surface of cells called cilia as such a common link. ... have links associated with the tiny, hair-like cilia and implications ...
... The State University of New Jersey have modified a ... stroke patients. The game helps with hand// exercises and ... effective that similar systems, which are more expensive. The ... stroke rehabilitation. ,Virtual rehabilitation gives therapists new ...
... St. Louis and other institutions have reported that experimental ... (PXR) my help in the treatment of Niemann-Pick type ... that is often fatal within the first two decades ... model for Niemann-Pick type C (NPC) disease showed that ...
Cached Medicine News:Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 2Health News:John Hopkins Develops An Online Tool To Help In Research Of Certain Rare Diseases 3Health News:Stroke Rehabilitation Through Modified Video Games 2Health News:Drugs Activating PXR May Help In Treating Niemann-Pick type C disease 2Health News:Drugs Activating PXR May Help In Treating Niemann-Pick type C disease 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: